Obesity Hypoventilation Syndrome Masked by Home Oximetry
A 48-year-old man with BMI 42 kg/m² presents with 2 years of loud snoring, witnessed apneas, and severe daytime sleepiness (Epworth 18). He has hypertension and prediabetes. Awake seated ABG: pH 7.38, PaCO2 47 mm Hg, PaO2 62 mm Hg, HCO3 29 mEq/L. Spirometry: FVC 72% predicted, FEV1/FVC 0.78; no obstruction. Overnight home oximetry shows recurrent desaturations to 68% with clusters, and baseline SpO2 89%. He denies orthopnea; exam shows JVP 6 cm, no edema, clear lungs. He is eager for a home sleep apnea test because it is cheaper.
1. Does this patient have obesity hypoventilation syndrome? What additional testing is needed before starting therapy?
Read the worked answer
He likely has obesity hypoventilation syndrome (OHS). The definition requires awake hypercapnia (PaCO2 ≥45 mm Hg) in a patient with obesity (BMI ≥30 kg/m²) after excluding other causes of hypoventilation. His PaCO2 is 47 mm Hg, he has a BMI of 42 kg/m², and he has no obstructive spirometric defect. The elevated bicarbonate suggests chronic hypercapnia.
However, before committing to OHS, exclude other causes:
- Hypothyroidism with TSH.
- Neuromuscular or chest wall disease with clinical assessment and, if suggested, further testing.
- Heart failure with history, exam, and echocardiogram if indicated.
- Medication effects, especially opioids or sedatives.
A home sleep apnea test is not adequate here because it cannot reliably measure CO2 or identify hypoventilation. He needs in-laboratory polysomnography with CO2 monitoring (end-tidal or transcutaneous) and assessment of sleep-related hypoventilation. Home oximetry alone underestimates the problem.
2. What initial PAP modality would you choose, and why?
Read the worked answer
Start with positive airway pressure titration during polysomnography. For OHS with coexisting obstructive sleep apnea, CPAP is often first-line because it can relieve upper airway obstruction and, in many patients, improve hypercapnia. However, if hypercapnia persists despite adequate CPAP adherence and control of obstructive events, bilevel positive airway pressure with a backup rate is preferred to augment alveolar ventilation.
The choice should be based on:
- Whether obstructive events predominate and are controlled on CPAP.
- Whether hypercapnia persists during titration.
- Patient comfort and adherence.
Avoid adaptive servoventilation if there is coexisting heart failure with reduced ejection fraction, because of safety concerns. In this patient, there is no evidence of heart failure, but the principle is to avoid unnecessary complexity. Adherence support, mask fitting, and humidification are as important as the mode itself.
3. What are the risks of untreated OHS, and what is the role of weight loss?
Read the worked answer
Untreated OHS carries substantial risk:
- Pulmonary hypertension and cor pulmonale from chronic hypoxemia and hypercapnia.
- Systemic hypertension, metabolic syndrome, and diabetes.
- Increased mortality, especially in hospitalized patients with hypercapnia.
- Motor vehicle accidents from daytime sleepiness.
- Postoperative respiratory failure and difficulty weaning from mechanical ventilation.
Weight loss is a key disease-modifying intervention. Even modest weight loss can improve hypercapnia and sleep-disordered breathing, and bariatric surgery can lead to remission in selected patients. However, weight loss takes time and should not delay PAP therapy. He should be referred to a structured weight-management program and counseled to avoid sedatives and opioids, which can worsen hypoventilation.
The judgment is to treat the hypoventilation now while addressing the underlying cause over the long term.